The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.
Interactive discussions with healthcare practitioners (HCPs) and patient education regarding multiple sclerosis (MS) relapse increases the likelihood of patients reporting relapses and achieving more proactive disease management
Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.
Study demonstrated efficacy in improving communication with the clinician, lowering the number of visits, and improving the coordination of single-day multi-service and therapeutic interventions in multiple sclerosis
Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis.
Despite the occurrence of thyroid adverse events or their severity, AEs had a minimal impact on quality of life for patients with relapsing-remitting multiple sclerosis who had been treated with alemtuzumab.
Investigators examine the use treatment patterns and utilization of disease-modifying therapy in newly diagnosed pediatric patients with multiple sclerosis.
Investigators sought to determine the 8-year safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis from the CARE-MS I and II studies.
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
The investigators of this study sought to evaluate the long-term efficacy and safety of alemtuzumab to treat patients of African descent who have relapsing-remitting MS.